{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T02:50:21Z","timestamp":1774493421606,"version":"3.50.1"},"reference-count":64,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000135","name":"NIH Blueprint for Neuroscience Research","doi-asserted-by":"publisher","award":["P30CA016359"],"award-info":[{"award-number":["P30CA016359"]}],"id":[{"id":"10.13039\/100000135","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.clindermatol.2019.10.015","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T02:01:53Z","timestamp":1571968913000},"page":"94-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["The life-threatening eruptions of immune checkpoint inhibitor therapy"],"prefix":"10.1016","volume":"38","author":[{"given":"Emily L","family":"Coleman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brianna","family":"Olamiju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan S","family":"Leventhal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2019.10.015_bb0005","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0010","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/cup.12858","article-title":"Diverse types of dermatologic toxicities from immune checkpoint blockade therapy","volume":"44","author":"Curry","year":"2017","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0015","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) v5.0","author":"National Cancer Institute","year":"2017"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0020","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1200\/JOP.18.00005","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline summary","volume":"14","author":"Brahmer","year":"2018","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0025","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0030","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jhep.2016.10.029","article-title":"Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma","volume":"66","author":"Duffy","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0035","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/annonc\/mdq013","article-title":"Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study","volume":"21","author":"O\u2019Day","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0040","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-09-1024","article-title":"A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma","volume":"15","author":"Weber","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0045","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0050","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaad.2014.02.035","article-title":"Ipilimumab in patients with cancer and the management of dermatologic adverse events","volume":"71","author":"Lacouture","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0055","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1684\/ejd.2017.3023","article-title":"Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective study","volume":"27","author":"Dika","year":"2017","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053745","article-title":"The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network","volume":"8","author":"Voskens","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0065","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/CMR.0000000000000326","article-title":"Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome","volume":"27","author":"Mirza","year":"2017","journal-title":"Melanoma Res"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0070","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/CMR.0000000000000261","article-title":"Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma","volume":"26","author":"Hwang","year":"2016","journal-title":"Melanoma Res"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0075","doi-asserted-by":"crossref","first-page":"e256","DOI":"10.1111\/jdv.14282","article-title":"Acute generalized exanthematous pustulosis associated with ipilimumab and nivolumab","volume":"32","author":"Page","year":"2018","journal-title":"J Eur Acad Dermatology Venereol"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0080","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1016\/j.jaad.2014.06.042","article-title":"Ipilimumab-associated Sweet syndrome in a melanoma patient","volume":"71","author":"Gormley","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0085","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/j.jaad.2013.11.022","article-title":"Ipilimumab-associated Sweet syndrome in a patient with high-risk melanoma","volume":"70","author":"Kyllo","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0090","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/CMR.0000000000000017","article-title":"Sweet\u2019s syndrome in a patient with metastatic melanoma after ipilimumab therapy","volume":"23","author":"Pintova","year":"2013","journal-title":"Melanoma Res"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0095","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamadermatol.2014.2233","article-title":"Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade","volume":"151","author":"Sheik Ali","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0100","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0105","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0110","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/1758834014567470","article-title":"Nivolumab in NSCLC: latest evidence and clinical potential","volume":"7","author":"Sundar","year":"2015","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0115","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.coph.2015.05.011","article-title":"PD-1\/PD-L1 inhibitors","volume":"23","author":"Sunshine","year":"2015","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0120","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1470-2045(17)30239-5","article-title":"Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial","volume":"18","author":"Heery","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0125","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1470-2045(17)30240-1","article-title":"Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial","volume":"18","author":"Gulley","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0130","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamadermatol.2016.2226","article-title":"Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy","volume":"152","author":"Shi","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0135","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor","volume":"60","author":"Belum","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0140","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/CCO.0000000000000290","article-title":"Dermatologic complications of anti-PD-1\/PD-L1 immune checkpoint antibodies","volume":"28","author":"Sibaud","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0145","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1111\/jdv.14011","article-title":"Anti-PD1-induced psoriasis: a study of 21 patients","volume":"31","author":"Bonigen","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0150","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jdcr.2016.05.002","article-title":"Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy","volume":"2","author":"Suozzi","year":"2016","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0155","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jdcr.2017.02.015","article-title":"Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma","volume":"3","author":"Birnbaum","year":"2017","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0160","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/annonc\/mdx642","article-title":"Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma","volume":"29","author":"Pollack","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0165","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jdcr.2017.09.028","article-title":"Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma","volume":"4","author":"Griffin","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0170","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/cup.12876","article-title":"Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy","volume":"44","author":"Vivar","year":"2017","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0175","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/CJI.0000000000000112","article-title":"Toxic epidermal necrolysis-like reaction with severe satellite cell necrosis associated with nivolumab in a patient with ipilimumab refractory metastatic melanoma","volume":"39","author":"Nayar","year":"2016","journal-title":"J Immunother"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0180","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.lungcan.2017.04.020","article-title":"Aprepitant for refractory nivolumab-induced pruritus","volume":"109","author":"Ito","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0185","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1177\/1078155218791314","article-title":"Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy","volume":"25","author":"Hwang","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0190","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ejca.2017.03.026","article-title":"Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients","volume":"81","author":"Saw","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0195","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.jtho.2018.05.031","article-title":"Stevens-Johnson syndrome induced by pembrolizumab in a lung cancer patient","volume":"13","author":"Haratake","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0200","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1214788","article-title":"Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma","volume":"5","author":"Liniker","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0205","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jdcr.2016.05.009","article-title":"Development of bullous pemphigoid during nivolumab therapy","volume":"2","author":"Damsky","year":"2016","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0210","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jaad.2018.07.008","article-title":"Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy","volume":"79","author":"Siegel","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0215","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jaad.2015.10.029","article-title":"Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort","volume":"74","author":"Hwang","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0220","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1158\/2326-6066.CIR-15-0123","article-title":"Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1","volume":"4","author":"Naidoo","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0225","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1158\/1078-0432.CCR-15-2872","article-title":"Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy","volume":"22","author":"Goldinger","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0230","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/1346-8138.13810","article-title":"Unexpected recalcitrant course of drug-induced erythema multiforme-like eruption and interstitial pneumonia sequentially occurring after nivolumab therapy","volume":"44","author":"Nomura","year":"2017","journal-title":"J Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000485910","article-title":"A case of erythema multiforme major developed after sequential use of two immune checkpoint inhibitors, nivolumab and ipilimumab, for advanced melanoma: possible implication of synergistic and\/or complementary immunomodulatory effects","volume":"10","author":"Utsunomiya","year":"2018","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0240","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jamadermatol.2017.0091","article-title":"Rituximab treatment of nivolumab-induced bullous pemphigoid","volume":"153","author":"Sowerby","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0245","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-related adverse events associated with anti-PD-1\/PD-L1 treatment for malignancies: a meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0250","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2147\/CMAR.S163391","article-title":"Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies","volume":"10","author":"Chen","year":"2018","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0255","first-page":"31","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome","volume":"6","author":"Choudhary","year":"2013","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0260","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/bjd.12501","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study","volume":"169","author":"Kardaun","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0265","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jaad.2015.07.017","article-title":"Acute generalized exanthematous pustulosis (AGEP): a review and update","volume":"73","author":"Szatkowski","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0270","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0275","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1684\/ejd.2014.2297","article-title":"Neutrophilic disease of the skin and intestines after ipilimumab treatment for malignant melanoma - simultaneous occurrence of pyoderma gangrenosum and colitis","volume":"24","author":"Rudolph","year":"2014","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0280","first-page":"167","article-title":"Diagnostic criteria for Sweet\u2019s syndrome","volume":"37","author":"Su","year":"1986","journal-title":"Cutis"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0285","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jdcr.2018.05.020","article-title":"Checkpoint inhibitor-associated cutaneous small vessel vasculitis","volume":"4","author":"Castillo","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0290","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jdcr.2018.06.022","article-title":"Pityriasis rubra pilaris-like erythroderma in the setting of pembrolizumab therapy responsive to acitretin","volume":"4","author":"Coleman","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0295","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbmt.2018.08.028","article-title":"Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation","volume":"25","author":"Ijaz","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0300","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/bmt.2016.111","article-title":"Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin\u2019s lymphoma","volume":"51","author":"Singh","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0305","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0310","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/CJI.0000000000000191","article-title":"Acute flare of bullous pemphigus with pembrolizumab used for treatment of metastatic urothelial cancer","volume":"41","author":"Garje","year":"2018","journal-title":"J Immunother"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0315","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/cup.13059","article-title":"Lupus-like cutaneous reaction following pembrolizumab: an immune-related adverse event associated with anti-PD-1 therapy","volume":"45","author":"Shao","year":"2018","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.clindermatol.2019.10.015_bb0320","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMc0904283","article-title":"anti-CTLA-4 antibody\u2013induced lupus nephritis","volume":"361","author":"Fadel","year":"2009","journal-title":"N Engl J Med"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X19301919?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X19301919?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:15:02Z","timestamp":1760033702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X19301919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0738081X19301919"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2019.10.015","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The life-threatening eruptions of immune checkpoint inhibitor therapy","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2019.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}